Drug Chatter -- Tracking biopharma stock chatter

Profile for Fate Therapeutics, Inc. (FATE)

« Back to company index

FATE Chatter Timeline

Stock Ticker for FATE

Most Active Tweeters for FATE

UserTweets
@SleekMoneycom 5
@tribepublic 4
@BFHBiotech 3
@THEtoddboone 3
@WeekHerald 3

Recent Tweets for FATE

tribepublic @tribepublic
$FATE Fate Therapeutics. Better #cells for better #therapies. #cancer #tumor #Immunotherapy. https://t.co/NHntiFKhu3 https://t.co/ZaEFo022sJ
September 25th 2017, 5:09pm
storminvestor @storminvestor
Fate Therapeutics $FATE Earning Favorable Media Coverage, Study Finds https://t.co/SVM9cd3Tpz
September 25th 2017, 12:09pm
SPNewsAnalysis @SPNewsAnalysis
Fate Therapeutics $FATE Earning Favorable Media Coverage, Study Finds https://t.co/PVlA6KRYCD
September 25th 2017, 12:09pm
CFinancialNews @CFinancialNews
Weekly Research Analysts’ Ratings Changes for Fate Therapeutics $FATE https://t.co/oa5oiANzws
September 25th 2017, 10:09am
intercooleronli @intercooleronli
Weekly Research Analysts’ Ratings Changes for Fate Therapeutics $FATE https://t.co/DpJTBXqMOn
September 25th 2017, 10:09am
IcemanTrading @IcemanTrading
$FATE Piercing candlestick pattern. Looking for continuation using the previous lows as support. #ICEMAN #ITA https://t.co/3JSPkFVGOi
September 24th 2017, 11:09am
SleekMoneycom @SleekMoneycom
Fate Therapeutics, Inc. $FATE Upgraded to “Buy” by Zacks Investment Research https://t.co/v2oUBo3gVw
September 24th 2017, 6:09am
KodiakCap @KodiakCap
https://t.co/jvjTDEeFwj ... $FATE / $JUNO partnership
September 23rd 2017, 8:09pm
dakotafinancial @dakotafinancial
Fate Therapeutics, Inc. $FATE Lowered to Sell at ValuEngine https://t.co/JnZkGn0GV9
September 23rd 2017, 12:09pm
SleekMoneycom @SleekMoneycom
Leerink Swann Reiterates “Outperform” Rating for Fate Therapeutics, Inc. $FATE https://t.co/xyGULjsAw9
September 23rd 2017, 12:09am
THEtoddboone @THEtoddboone
RT @tribepublic: $FATE Therapeutics is developing adaptive #natural killer cells with cellular memory & anti #tumor properties. https://t.c…
September 22nd 2017, 9:09pm
CFinancialNews @CFinancialNews
Fate Therapeutics, Inc. $FATE Lowered to “Sell” at ValuEngine https://t.co/UCsHgo0VbE
September 22nd 2017, 10:09am
intercooleronli @intercooleronli
Fate Therapeutics, Inc. $FATE Lowered to “Sell” at ValuEngine https://t.co/QGfM1mwxn5
September 22nd 2017, 10:09am
WatchlistN @WatchlistN
Fate Therapeutics, Inc. $FATE Rating Lowered to Sell at ValuEngine https://t.co/UgJfw8ERDT
September 22nd 2017, 8:09am
RatingsNetwork @RatingsNetwork
Fate Therapeutics downgraded by ValuEngine to sell. https://t.co/Up2A2lbbhi $FATE #FATE
September 22nd 2017, 8:09am
4thQuarterCap @4thQuarterCap
Trimmed $FATE +27% in longterm account.
September 21st 2017, 7:09pm
WatchlistN @WatchlistN
-$0.25 EPS Expected for Fate Therapeutics, Inc. $FATE This Quarter https://t.co/eb0B6nRQKw
September 21st 2017, 12:09pm
CFinancialNews @CFinancialNews
-$0.25 EPS Expected for Fate Therapeutics, Inc. $FATE This Quarter https://t.co/qNXNSaqCCt
September 21st 2017, 12:09pm
ProVesting @ProVesting
$FATE: What ‘Fate’ Lies Ahead For This ~$4 Biotech Busted IPO?: https://t.co/EJvE1YfpTF
September 21st 2017, 12:09pm
SA_BioTech @SA_BioTech
https://t.co/5Aw24MTM1q $FATE
September 21st 2017, 12:09pm
SeekingAlpha @SeekingAlpha
https://t.co/dK5A8XUgm9 $FATE
September 21st 2017, 12:09pm
ZolmaxNews @ZolmaxNews
Franklin Resources Inc. Has $19,689,000 Position in Fate Therapeutics, Inc. $FATE https://t.co/u0JdZDLXpg
September 21st 2017, 7:09am
BFHBiotech @BFHBiotech
@JasonHolman5 Can't wait for $FATE NK story to shape up, love their tech - think it's a super cool approach. And… https://t.co/ggd6ZBJEVw
September 20th 2017, 9:09pm
tribepublic @tribepublic
$FATE Therapeutics is developing adaptive #natural killer cells with cellular memory & anti #tumor properties.… https://t.co/waQlvAWAba
September 20th 2017, 6:09pm
bret_jensen @bret_jensen
$FATE #biotech Our latest take on this small CAR-T concern https://t.co/Jk78gfx5GM
September 20th 2017, 5:09pm
bret_jensen @bret_jensen
$FATE What Will Be The FATE Of This ~$4 'Busted IPO' https://t.co/b7sBf2Rgzk
September 20th 2017, 2:09pm
noritsunagirota @noritsunagirota
Fate Therapeutics $FATE Share Price Rose While Kingdon Capital Management Has Cut Its Stake ...
September 20th 2017, 9:09am
SleekMoneycom @SleekMoneycom
Somewhat Positive News Coverage Somewhat Unlikely to Impact Fate Therapeutics $FATE Share Price https://t.co/67Q67Eunjv
September 20th 2017, 8:09am
VistaPResearch @VistaPResearch
RT @tribepublic: $Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease. https:/…
September 19th 2017, 10:09pm
TickerReport @TickerReport
Fate Therapeutics $FATE Getting Favorable Press Coverage, Study Finds https://t.co/WkKZm6s1FY
September 19th 2017, 9:09am
emq_news @emq_news
Fate Therapeutics $FATE Getting Favorable Press Coverage, Study Finds https://t.co/E12cMzFbpF
September 19th 2017, 9:09am
TickerReport @TickerReport
Fate Therapeutics $FATE Getting Favorable Press Coverage, Study Finds https://t.co/gaf47NamkD
September 19th 2017, 9:09am
tribepublic @tribepublic
$Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease. https://t.co/gVXaudwmXk
September 18th 2017, 4:09pm
Nonfiction8879 @Nonfiction8879
Fate Therapeutics launches mid-stage study of ProTmune in GvHD; shares ahead 3% $FATE https://t.co/aZeu0Xh3Sr
September 18th 2017, 1:09pm
SEEKINGALPHA_FS @SEEKINGALPHA_FS
Fate Therapeutics launches mid-stage study of ProTmune in GvHD; shares ahead 3% https://t.co/5v8VddAuHl $FATE
September 18th 2017, 1:09pm
MarketCurrents @MarketCurrents
Fate Therapeutics launches mid-stage study of ProTmune in GvHD; shares ahead 3% https://t.co/aOGr8InfJh $FATE
September 18th 2017, 1:09pm
Briefingcom @Briefingcom
$FATE: Fate Therapeutics initiates Phase 2 stage of PROTECT the prevention of acute graft-versus-host disease in... https://t.co/YMmbnrB4tn
September 18th 2017, 10:09am
BFHBiotech @BFHBiotech
@JasonHolman5 Would like to see $FATE initiate more clinical dev programs going into 2018 - a lot riding on ProTmune right now
September 18th 2017, 10:09am
BFHBiotech @BFHBiotech
@JasonHolman5 Agreed - nice update from $FATE today. Will be interesting to see comp to BPX501, although v diff products ??
September 18th 2017, 10:09am
JasonHolman5 @JasonHolman5
https://t.co/E9R5ZqazpL Things progressing well for $FATE ProTmune study prgrssing well(PH2 now);[email protected]&see whats comparable to $BLCM 501.
September 18th 2017, 9:09am
newswelldone @newswelldone
$FATE: Fate Therapeutics (FATE) Initiates Phase 2 PROTECT Study of …: https://t.co/aVjvdGdbQ6
September 18th 2017, 8:09am
stocknewsdotcom @stocknewsdotcom
$FATE Initiates Phase 2 stage of PROTECT the prevention of acute graft-versus-host disease in patients with hemato… https://t.co/wkbtO0Eja3
September 18th 2017, 8:09am
stockboardinc @stockboardinc
$FATE Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versu... - https://t.co/LqTaDdstcz
September 18th 2017, 8:09am
GNWLive @GNWLive
Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host $FATE https://t.co/ZZ5hdVw2Vy
September 18th 2017, 8:09am
SleekMoneycom @SleekMoneycom
Zacks Investment Research Upgrades Fate Therapeutics, Inc. $FATE to “Buy” https://t.co/v2oUBo3gVw
September 16th 2017, 2:09pm
WeekHerald @WeekHerald
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Fate Therapeutics $FATE Stock Price https://t.co/WwSgjPgzlV
September 16th 2017, 1:09am
WeekHerald @WeekHerald
Zacks Investment Research Upgrades Fate Therapeutics, Inc. $FATE to “Buy” https://t.co/pzsjtHhT1i
September 15th 2017, 11:09pm
THEtoddboone @THEtoddboone
RT @tribepublic: $FATE Therapeutics designs off-the-shelf cellular #immunotherapies providing solutions for #immune disorders. https://t.co…
September 15th 2017, 6:09pm
THEtoddboone @THEtoddboone
RT @tribepublic: $FATE Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development. https://t.co/KscQlvitsF
September 15th 2017, 6:09pm
SleekMoneycom @SleekMoneycom
Fate Therapeutics, Inc. $FATE Stock Rating Reaffirmed by Leerink Swann https://t.co/xyGULjsAw9
September 15th 2017, 8:09am

Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.